| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anastasiia S Boiko, Irina A Mednova, Elena G Kornetova, Valeria I Gerasimova, Alexander N Kornetov, Anton J M Loonen, Nikolay A Bokhan, Svetlana A Ivanov. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals (Basel, Switzerland). vol 14. issue 5. 2021-06-15. PMID:34065135. |
the present study aims at comparing the change in cytokine levels in schizophrenia patients treated with atypical antipsychotics, with or without metabolic syndrome (mets). |
2021-06-15 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Guilherme L Alexandrino, Adriano Aquino, Alexandre F Gomes, Michael Murgu, Henrik Dobrowolny, Paul C Guest, Johann Steiner, Daniel Martins-de-Souz. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 101. 2021-06-04. PMID:32304808. |
atypical antipsychotics are widely used to manage schizophrenia symptoms. |
2021-06-04 |
2023-08-13 |
Not clear |
| Xue-Lin Chao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bo Wei, Chun-Nuan Chen, Yuan-Jian Yan. Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current medical science. vol 40. issue 3. 2021-05-18. PMID:32681260. |
changes of serum insulin-like growth factor-2 response to negative symptom improvements in schizophrenia patients treated with atypical antipsychotics. |
2021-05-18 |
2023-08-13 |
Not clear |
| Xue-Lin Chao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bo Wei, Chun-Nuan Chen, Yuan-Jian Yan. Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current medical science. vol 40. issue 3. 2021-05-18. PMID:32681260. |
here we conducted a prospective observation trial to investigate the effects of atypical antipsychotics on serum igf-2 level and its relationship with clinical improvements in schizophrenia patients. |
2021-05-18 |
2023-08-13 |
Not clear |
| Xue-Lin Chao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bo Wei, Chun-Nuan Chen, Yuan-Jian Yan. Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current medical science. vol 40. issue 3. 2021-05-18. PMID:32681260. |
collectively, our findings demonstrated changes of serum igf-2 response to improvements of negative symptoms in schizophrenia patients treated with atypical antipsychotics, suggesting that serum igf-2 might be a treatment biomarker for schizophrenia. |
2021-05-18 |
2023-08-13 |
Not clear |
| Gulshan Begum, Stanley Nkemjika, Olaniyi Olayinka, Tolu Olupona, Ayodeji Jolayem. Clozapine Response for Vocal Tics in Schizophrenic Patients: A Case Report With Literature Review. Cureus. vol 13. issue 3. 2021-04-29. PMID:33907647. |
additionally, evidence in the literature has shown that typical and atypical antipsychotics are effective for the treatment of tic disorders in patients who are diagnosed with schizophrenia and other psychiatric illnesses. |
2021-04-29 |
2023-08-13 |
Not clear |
| Samantha Alvarez-Herrera, Raúl Escamilla, Oscar Medina-Contreras, Ricardo Saracco, Yvonne Flores, Gabriela Hurtado-Alvarado, José Luis Maldonado-García, Enrique Becerril-Villanueva, Gilberto Pérez-Sánchez, Lenin Pavó. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Frontiers in endocrinology. vol 11. 2021-04-01. PMID:32373066. |
atypical antipsychotics (aap) or second-generation antipsychotics are the clinical option for schizophrenia treatment during acute psychoses, but they are also indicated for maintenance during lifetime, even though they are being used for other psychiatric conditions in clinical practice such as affective disorders and autism spectrum disorder, among others. |
2021-04-01 |
2023-08-13 |
Not clear |
| Wenjuan Yu, Jingjing Huang, Sidi He, Lei Zhang, Yifeng Shen, Huafang L. Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study. General psychiatry. vol 34. issue 1. 2021-03-03. PMID:33644688. |
atypical antipsychotics as first-line drugs have been used in patients with schizophrenia in china and abroad. |
2021-03-03 |
2023-08-13 |
Not clear |
| Mehran Zarghami, Seyed Davood Hoseini, Arash Kazemi, Forouzan Elyas. Concurrent Hepatotoxicity and Neutropenia Induced by Clozapine. Archives of Iranian medicine. vol 23. issue 2. 2021-01-06. PMID:32061077. |
clozapine is known as one of the atypical antipsychotics which is placed in the second line of medical treatment for schizophrenia due to its hematologic complications. |
2021-01-06 |
2023-08-13 |
Not clear |
| Giuseppe Caruso, Margherita Grasso, Annamaria Fidilio, Fabio Tascedda, Filippo Drago, Filippo Carac. Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia. Pharmaceuticals (Basel, Switzerland). vol 13. issue 12. 2020-12-29. PMID:33322693. |
opposite to haloperidol, second-generation antipsychotics (or atypical antipsychotics) such as risperidone, clozapine, and olanzapine exert a strong antioxidant activity in experimental models of schizophrenia by rescuing the antioxidant system, with an increase in superoxide dismutase and glutathione (gsh) serum levels. |
2020-12-29 |
2023-08-13 |
Not clear |
| Yanyan Hou, Jiaheng Xie, Yanbo Yuan, Zhang Cheng, Xue Han, Lei Yang, Xin Yu, Chuan Sh. Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. Nordic journal of psychiatry. vol 74. issue 8. 2020-11-20. PMID:32496921. |
neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. |
2020-11-20 |
2023-08-13 |
Not clear |
| Gregory Oxenkrug, Paul Summergra. Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice. Molecular neurobiology. vol 57. issue 1. 2020-11-19. PMID:31515691. |
schizophrenia (sz) patients, especially treated with atypical antipsychotics, are at high risk of the development of metabolic syndrome that increases morbidity and mortality and impairs compliance with treatment. |
2020-11-19 |
2023-08-13 |
mouse |
| Mirela Tiglis, Tudor Hurmuzache, Cristina Bologa, Tiberiu Paul Neagu, Liliana Mirea, Ioana Marina Grintesc. Rhabdomyolysis-Induced Acute Renal Injury in a Schizophrenic Patient. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures). vol 6. issue 4. 2020-11-18. PMID:33200097. |
nowadays, schizophrenia is treated with atypical antipsychotics that can determine neuroleptic malignant syndrome or rhabdomyolysis appearance. |
2020-11-18 |
2023-08-13 |
Not clear |
| Xue-Lin Chao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bo Wei, Chun-Nuan Chen, Yuan-Jian Yan. Erratum to: Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current medical science. vol 40. issue 5. 2020-11-12. PMID:33123913. |
erratum to: changes of serum insulin-like growth factor-2 response to negative symptom improvements in schizophrenia patients treated with atypical antipsychotics. |
2020-11-12 |
2023-08-13 |
Not clear |
| Xue-Lin Chao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bo Wei, Chun-Nuan Chen, Yuan-Jian Yan. Erratum to: Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current medical science. vol 40. issue 5. 2020-11-12. PMID:33123913. |
the article "changes of serum insulin-like growth factor-2 response to negative symptom improvements in schizophrenia patients treated with atypical antipsychotics", written by xue-lin chao, shu-zhen jiang, jian-wen xiong, jin-qiong zhan, bo wei, chun-nuan chen, yuan-jian yang was originally published electronically on the publisher's internet portal on june 2020 without open access. |
2020-11-12 |
2023-08-13 |
Not clear |
| Antoine C El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Amanda Llaneza, Edward Kim, Patrick Lefebvr. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of managed care & specialty pharmacy. vol 26. issue 2. 2020-11-05. PMID:32011960. |
projecting the long-term economic impact of once-monthly paliperidone palmitate versus oral atypical antipsychotics in medicaid patients with schizophrenia. |
2020-11-05 |
2023-08-13 |
Not clear |
| Jacqueline A Pesa, Erik Muser, Leslie B Montejano, David M Smith, Oren I Meyer. Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics. Drugs - real world outcomes. vol 2. issue 4. 2020-10-01. PMID:26689953. |
costs and resource utilization among medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. |
2020-10-01 |
2023-08-13 |
Not clear |
| Gary Remington, George Foussias, Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, Margaret Hah. Treating Negative Symptoms in Schizophrenia: an Update. Current treatment options in psychiatry. vol 3. 2020-10-01. PMID:27376016. |
strategies include use of atypical antipsychotics, ensuring the lowest possible antipsychotic dose that maintains control of positive symptoms (this can involve a shift from antipsychotic polypharmacy to monotherapy), possibly an antidepressant trial (given diagnostic uncertainty and the frequent use of these drugs in schizophrenia), and non-somatic interventions (e.g., cognitive behavioral therapy, cbt). |
2020-10-01 |
2023-08-13 |
human |
| Xin Yu, Christoph U Correll, Yu-Tao Xiang, Yifeng Xu, Jizhong Huang, Fude Yang, Gang Wang, Tianmei Si, John M Kane, Prakash Masan. Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. Shanghai archives of psychiatry. vol 28. issue 5. 2020-10-01. PMID:28638198. |
efficacy of atypical antipsychotics in the management of acute agitation and aggression in hospitalized patients with schizophrenia or bipolar disorder: results from a systematic review. |
2020-10-01 |
2023-08-13 |
Not clear |
| Xin Yu, Christoph U Correll, Yu-Tao Xiang, Yifeng Xu, Jizhong Huang, Fude Yang, Gang Wang, Tianmei Si, John M Kane, Prakash Masan. Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. Shanghai archives of psychiatry. vol 28. issue 5. 2020-10-01. PMID:28638198. |
among available approaches, we discuss in detail recent evidence supporting the use of intramuscular (im) antipsychotics and some recently approved oral atypical antipsychotics for the management of acute aggression and agitation in hospitalized patients with bipolar disorder or schizophrenia presenting with acute agitation or aggression, highlighting some differences between individual antipsychotic agents. |
2020-10-01 |
2023-08-13 |
Not clear |